Unicycive Therapeutics Inc. Common Stock (UNCY)
Stock · NASDAQ · Health Care
$3.36as of 10/16/2026
Price chart
Active signals
UNCY Signal Track Record
How signals performed across all stocks →What UNCY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +5.3% | 54% | September 29, 2026 |
| Bollinger Band BreakdownActive now | 20 | -3.1% | 50% | October 2, 2026 |
| Bollinger Band Breakout | 21 | +4.1% | 57% | June 23, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -13.3% | 29% | November 13, 2025 |
| Any 20-session window (baseline) | -2.8% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About UNCY
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 21
- Website
- unicycive.com/
Fundamentals
- 1-day range
- $3.35$3.58
- Market cap
- $138.33M
- P/E (trailing)
- —
- P/E (forward)
- 1.99
- EPS (trailing)
- $-1.62
- Dividend yield
- —
- Beta
- 1.77
- Avg. volume
- 842.1K
How Unicycive Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 31, 2023 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Unicycive Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- UNCYUnicycive Therapeutics Inc. Common Stock$3.36▼ 6.41%Market cap $138.33MP/E —$3.56$8.74
- CNTBConnect Biopharma Holdings Limited Ordinary Shares$0.906▲ 0.00%Market cap $137.89MP/E —$0.8501$3.82
- OGIOrganigram Global Inc. Common Shares$0.927▼ 0.54%Market cap $139.37MP/E 2.08$1.2$3.09
- VTVTvTv Therapeutics Inc. Class A Common Stock$26.54▼ 3.81%Market cap $136.33MP/E 55.59$19.5$44
- KZIAKazia Therapeutics Limited American Depositary Shares$7.25▼ 2.03%Market cap $140.89MP/E —$4.86$17.4
- NGENNervGen Pharma Corp. Common stock$1.59▼ 1.85%Market cap $141.37MP/E —$3.2$8.49
- HURATuHURA Biosciences Inc. Common Stock$1.76▼ 3.83%Market cap $134.69MP/E —$0.41$3.43
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| UNCY Unicycive Therapeutics Inc. Common Stock | $138.33M | — | $3.36 | ▼ 6.41% | $3.56$8.74 |
| CNTB Connect Biopharma Holdings Limited Ordinary Shares | $137.89M | — | $0.906 | ▲ 0.00% | $0.8501$3.82 |
| OGI Organigram Global Inc. Common Shares | $139.37M | 2.08 | $0.927 | ▼ 0.54% | $1.2$3.09 |
| VTVT vTv Therapeutics Inc. Class A Common Stock | $136.33M | 55.59 | $26.54 | ▼ 3.81% | $19.5$44 |
| KZIA Kazia Therapeutics Limited American Depositary Shares | $140.89M | — | $7.25 | ▼ 2.03% | $4.86$17.4 |
| NGEN NervGen Pharma Corp. Common stock | $141.37M | — | $1.59 | ▼ 1.85% | $3.2$8.49 |
| HURA TuHURA Biosciences Inc. Common Stock | $134.69M | — | $1.76 | ▼ 3.83% | $0.41$3.43 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Unicycive Therapeutics Appoints Meredith Manning to Board of DirectorsYahoo · 10/1/2026
- HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13Benzinga · 9/29/2026
- Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum CarbonateYahoo · 9/29/2026
- Unicycive Therapeutics Resubmits Its FDA New Drug Application For Oxylanthanum Carbonate For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Expects PDUFA Date Six Months From Resubmission DateBenzinga · 9/29/2026
- Unicycive Says Suit Alleges Securities Law Violations Over Statements On Oxylanthanum Carbonate FDA ApplicationBenzinga · 9/28/2026
- Unicycive Therapeutics Discloses Securities Class Action Filed September 3 Against Company And Certain OfficersBenzinga · 9/28/2026
Insider Activity
Insider Actions →- Sara Kenkare-Mitra · May 14, 2026 · Grant47.9K
- Sandeep Laumas · May 14, 2026 · Grant47.9K
- Gupta Shalabh K. · May 14, 2026 · Grant762.2K
- Sara Kenkare-Mitra · May 14, 2026 · Grant42.1K
- Sara Kenkare-Mitra · May 14, 2026 · Grant84.2K
- Gupta Pramod · May 14, 2026 · Grant169.5K
- Jermasek Douglas · May 14, 2026 · Grant169.5K
- Sandeep Laumas · May 14, 2026 · Grant42.1K
- Sandeep Laumas · May 14, 2026 · Grant84.2K
- Townsend John · May 14, 2026 · Grant169.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 10.39M
- Total value held
- $67.93M
- Institutional holders
- 49
- Unknown1.79M
- Unknown1.40M
- Unknown1.00M
- Unknown939.2K
- Unknown811.4K
- Unknown796.6K
- Unknown598.3K
- Unknown473.6K
- Unknown344.7K
- Unknown225.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Unicycive Resubmits FDA Application Amid Securities Lawsuit
Unicycive Therapeutics has resubmitted its FDA application for oxylanthanum carbonate, targeting a PDUFA date six months from now. This regulatory update comes alongside a securities class action filed in September, alleging violations related to previous statements about the drug application. The stock is currently trading near its 52-week low, reflecting the combined weight of legal and regulatory developments.
Unicycive Resubmits FDA Application Amid Securities Lawsuit. Unicycive Therapeutics has resubmitted its FDA application for oxylanthanum carbonate, targeting a PDUFA date six months from now. This regulatory update comes alongside a securities class action filed in September, alleging violations related to previous statements about the drug application. The stock is currently trading near its 52-week low, reflecting the combined weight of legal and regulatory developments.